Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans.

IF 1.7 3区 医学 Q4 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Pharmacogenetics and genomics Pub Date : 2023-07-01 Epub Date: 2023-04-24 DOI:10.1097/FPC.0000000000000491
Somila Mateza, Yuki Bradford, Gary Maartens, Simiso Sokhela, Nomathemba C Chandiwana, Willem D F Venter, Frank A Post, Marylyn D Ritchie, David W Haas, Phumla Sinxadi
{"title":"Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans.","authors":"Somila Mateza, Yuki Bradford, Gary Maartens, Simiso Sokhela, Nomathemba C Chandiwana, Willem D F Venter, Frank A Post, Marylyn D Ritchie, David W Haas, Phumla Sinxadi","doi":"10.1097/FPC.0000000000000491","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Renal toxicity is more common with tenofovir disoproxil fumarate (TDF) than with tenofovir alafenamide fumarate (TAF). We investigated whether polymorphisms in genes relevant to tenofovir disposition affect renal toxicity among HIV-positive Southern Africans.</p><p><strong>Methods: </strong>Genetic sub-study of adults randomized to initiate TAF or TDF together with dolutegravir and emtricitabine was conducted. Outcomes were changes from week 4 to 48 in the estimated glomerular filtration rate (eGFR) and from baseline to week 48 in urine retinol-binding protein and urine β2-microglobulin adjusted for urinary creatinine (uRBP/Cr and uB2M/Cr). Primary analyses prioritized 14 polymorphisms previously reported to be associated with tenofovir disposition or renal outcomes, and all polymorphisms in 14 selected genes. We also explored genome-wide associations.</p><p><strong>Results: </strong>336 participants were enrolled. Among 14 polymorphisms of primary interest, the lowest P values for change in eGFR, uRBP/Cr, and uB2M/Cr were ABCC4 rs899494 ( P  = 0.022), ABCC10 rs2125739 ( P  = 0.07), and ABCC4 rs1059751 ( P  = 0.0088); and in genes of interest, the lowest P values were ABCC4 rs4148481 ( P  = 0.0013), rs691857 ( P  = 0.00039), and PKD2 rs72659631 ( P  = 0.0011). However, none of these polymorphisms withstood correction for multiple testing. Genome-wide, the lowest P values were COL27A1 rs1687402 ( P  = 3.4 × 10 -9 ), CDH4 rs66494466 ( P  = 5.6 × 10 -8 ), and ITGA4 rs3770126 ( P  = 6.1 × 10 -7 ).</p><p><strong>Conclusion: </strong>Two ABCC4 polymorphisms, rs899494 and rs1059751, were nominally associated with change in eGFR and uB2M/Cr, respectively, albeit in the opposite direction of previous reports. COL27A1 polymorphism was genome-wide significantly associated with change in eGFR.</p>","PeriodicalId":19763,"journal":{"name":"Pharmacogenetics and genomics","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234323/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenetics and genomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FPC.0000000000000491","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Renal toxicity is more common with tenofovir disoproxil fumarate (TDF) than with tenofovir alafenamide fumarate (TAF). We investigated whether polymorphisms in genes relevant to tenofovir disposition affect renal toxicity among HIV-positive Southern Africans.

Methods: Genetic sub-study of adults randomized to initiate TAF or TDF together with dolutegravir and emtricitabine was conducted. Outcomes were changes from week 4 to 48 in the estimated glomerular filtration rate (eGFR) and from baseline to week 48 in urine retinol-binding protein and urine β2-microglobulin adjusted for urinary creatinine (uRBP/Cr and uB2M/Cr). Primary analyses prioritized 14 polymorphisms previously reported to be associated with tenofovir disposition or renal outcomes, and all polymorphisms in 14 selected genes. We also explored genome-wide associations.

Results: 336 participants were enrolled. Among 14 polymorphisms of primary interest, the lowest P values for change in eGFR, uRBP/Cr, and uB2M/Cr were ABCC4 rs899494 ( P  = 0.022), ABCC10 rs2125739 ( P  = 0.07), and ABCC4 rs1059751 ( P  = 0.0088); and in genes of interest, the lowest P values were ABCC4 rs4148481 ( P  = 0.0013), rs691857 ( P  = 0.00039), and PKD2 rs72659631 ( P  = 0.0011). However, none of these polymorphisms withstood correction for multiple testing. Genome-wide, the lowest P values were COL27A1 rs1687402 ( P  = 3.4 × 10 -9 ), CDH4 rs66494466 ( P  = 5.6 × 10 -8 ), and ITGA4 rs3770126 ( P  = 6.1 × 10 -7 ).

Conclusion: Two ABCC4 polymorphisms, rs899494 and rs1059751, were nominally associated with change in eGFR and uB2M/Cr, respectively, albeit in the opposite direction of previous reports. COL27A1 polymorphism was genome-wide significantly associated with change in eGFR.

Abstract Image

Abstract Image

Abstract Image

艾滋病毒呈阳性的南部非洲人的替诺福韦肾毒性药物遗传学。
目的:与富马酸替诺福韦酯(TAF)相比,富马酸替诺福韦酯(TDF)更容易引起肾毒性。我们研究了与替诺福韦处置相关的基因多态性是否会影响 HIV 阳性的南部非洲人的肾毒性:对随机接受 TAF 或 TDF 以及多鲁曲韦和恩曲他滨治疗的成人进行了基因亚研究。研究结果为第 4 周至第 48 周估计肾小球滤过率(eGFR)的变化,以及基线至第 48 周尿液视黄醇结合蛋白和尿液β2-微球蛋白(经尿肌酐调整)(uRBP/Cr 和 uB2M/Cr)的变化。初步分析优先考虑了之前报道的与替诺福韦处置或肾脏结果相关的 14 个多态性,以及 14 个选定基因中的所有多态性。我们还探讨了全基因组关联:结果:336 人参加了研究。在主要关注的 14 个多态性中,eGFR、uRBP/Cr 和 uB2M/Cr 变化的最低 P 值分别为 ABCC4 rs899494 ( P = 0.022)、ABCC10 rs2125739 ( P = 0. 07) 和 ABCC4 rs899494 ( P = 0.022)。07)、ABCC4 rs1059751 ( P = 0.0088);而在相关基因中,P 值最低的是 ABCC4 rs4148481 ( P = 0.0013)、rs691857 ( P = 0.00039)和 PKD2 rs72659631 ( P = 0.0011)。然而,这些多态性都经不起多重检验校正。在全基因组范围内,P 值最低的是 COL27A1 rs1687402(P = 3.4 × 10 -9)、CDH4 rs66494466(P = 5.6 × 10 -8)和 ITGA4 rs3770126(P = 6.1 × 10 -7):ABCC4的两个多态性rs899494和rs1059751分别与eGFR和uB2M/Cr的变化有名义上的相关性,尽管与之前的报道方向相反。COL27A1 多态性在全基因组范围内与 eGFR 的变化显著相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmacogenetics and genomics
Pharmacogenetics and genomics 医学-生物工程与应用微生物
CiteScore
3.20
自引率
3.80%
发文量
47
审稿时长
3 months
期刊介绍: ​​​​Pharmacogenetics and Genomics is devoted to the rapid publication of research papers, brief review articles and short communications on genetic determinants in response to drugs and other chemicals in humans and animals. The Journal brings together papers from the entire spectrum of biomedical research and science, including biochemistry, bioinformatics, clinical pharmacology, clinical pharmacy, epidemiology, genetics, genomics, molecular biology, pharmacology, pharmaceutical sciences, and toxicology. Under a single cover, the Journal provides a forum for all aspects of the genetics and genomics of host response to exogenous chemicals: from the gene to the clinic.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信